Centessa Pharmaceuticals (CNTA) announced the appointment of April Dovholuk and Ellie Im, MD to Centessa’s executive team as Senior Vice President of Development Operations and Senior Vice President of Clinical Development, Oncology, respectively. In these newly created roles, Ms. Dovholuk will lead both Centessa’s global Clinical Trials and Development Operations teams, and Dr. Im will manage clinical development of the Company’s Oncology programs based on the LockBody technology platform. Prior to joining Centessa, Ms. Dovholuk was Senior Vice President, Clinical Development Operations at Replimune (REPL). Im most recently served as Senior Vice President, Clinical Development and Operations at Mersana Therapeutics (MRSN).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CNTA:
- Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress
- Centessa price target raised to $10 from $9 at Guggenheim
- Centessa price target raised to $11 from $6 at SVB Securities
- Centessa reports Q2 EPS (26c), consensus (49c)
- Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023
